initialTreatment	initialTreatment_class	renameInitialTreatment	simpleInitialTreatment
Dauno/Ara-C	7+3	7+3	anthracycline_nucleosideAnalog
Ida/Ara-C	7+3	7+3	anthracycline_nucleosideAnalog
7+3 Dauno/Ara-C	7+3	7+3	anthracycline_nucleosideAnalog
7+3	7+3	7+3	anthracycline_nucleosideAnalog
Idarubicin/Cytarabine	7+3	7+3	anthracycline_nucleosideAnalog
Idarubicin/ Cytarabine	7+3	7+3	anthracycline_nucleosideAnalog
Clofarabine 7/5/2013;Ida/Ara-C	7+3	7+3	anthracycline_nucleosideAnalog
7+3 (daunorubicin 90 mg/m2 days 1-3 and cytarabine 100 mg/m2 days 1-7)	7+3	7+3	anthracycline_nucleosideAnalog
Vyxeos	Vyxeos	7+3	anthracycline_nucleosideAnalog
Idarubicin 12 mg/m2 and cytarabine 1500 mg/m2	7+3	7+3	anthracycline_nucleosideAnalog
"Idarubicin 12 mg/m2 IV D1-3, Cytarabine 100 mg/m2 IV D1-7"	7+3	7+3	anthracycline_nucleosideAnalog
7+3 +/- quizartinib	7+3	7+3+quizartinib	anthracycline_nucleosideAnalog_FLT3i
idarubicin and cytarabine	7+3	7+3	anthracycline_nucleosideAnalog
7+ 3	7+3	7+3	anthracycline_nucleosideAnalog
Daunorubicin 60mg/m2 + Ara-c + Gemtuzumab Ozogamicin	7+3	7+3+gemtuzumab	anthracycline_nucleosideAnalog_CD33ab
7+3 + Mylotarg	7+3	7+3+gemtuzumab	anthracycline_nucleosideAnalog_CD33ab
Dauna/AraC with Gemtuzumab	7+3	7+3+gemtuzumab	anthracycline_nucleosideAnalog_CD33ab
"UPCC 27414 induction:Idarubicin 12 mg/m2/d, d1-3Ara-C 100 mg/m2/d"	7+3	7+3+gilteritinib	anthracycline_nucleosideAnalog_FLT3i
Ida/Ara-C + ASP2215	7+3	7+3+gilteritinib	anthracycline_nucleosideAnalog_FLT3i
Ida/Ara-C + ASP2216	7+3	7+3+gilteritinib	anthracycline_nucleosideAnalog_FLT3i
7+3 and midostaurin	7+3	7+3+midostaurin	anthracycline_nucleosideAnalog_FLT3i
Daunorubicin and Cytarabine + Midostaurin	7+3	7+3+midostaurin	anthracycline_nucleosideAnalog_FLT3i
7+3 Dauna/Ara-C + Midostaurin	7+3	7+3+midostaurin	anthracycline_nucleosideAnalog_FLT3i
(7+3) with Midostaurin	7+3	7+3+midostaurin	anthracycline_nucleosideAnalog_FLT3i
Ida/Ara-C + Vorinostat	7+3	7+3+vorinostat	anthracycline_nucleosideAnalog_HDAC
ATRA / ATO	ATRA / ATO	ATRA/ATO	ATRA_ATO
ATRAx4 doses; Dauno/Ara-C + Cellerant	ATRA / ATO	ATRA/ATO	ATRA_ATO
S/P ATO	ATRA / ATO	ATRA/ATO	ATRA_ATO
Vidaza at 100 mg/mÂ²	HMA	azacitidine monotherapy	HMA_monotherapy
Vidaza 75 mg/m2	HMA	azacitidine monotherapy	HMA_monotherapy
5-azacitidine 75 mg/m2 IV	HMA	azacitidine monotherapy	HMA_monotherapy
Vidaza	HMA	azacitidine monotherapy	HMA_monotherapy
Clofarabine ECOG 2906	Clofarabine	clofarabine monotherapy	nucleosideAnalog_monotherapy
Clofarabine ECOG 2907	Clofarabine	clofarabine monotherapy	nucleosideAnalog_monotherapy
Clofarabine ECOG 2908	Clofarabine	clofarabine monotherapy	nucleosideAnalog_monotherapy
Ara-C	7+3	cytarabine monotherapy	nucleosideAnalog_monotherapy
LDAC	LDAC	cytarabine monotherapy	nucleosideAnalog_monotherapy
LDAC+Lintuzumab	LDAC	cytarabine+lintuzumab	nucleosideAnalog_CD33ab
Decitabine 20 mg/m2 X 3 days q 28 days started	HMA	decitabine monotherapy	HMA_monotherapy
Dacogen	HMA	decitabine monotherapy	HMA_monotherapy
Idarubicin/HDAC	Idarubicin/HDAC	Idarubicin/HDAC	anthracycline_HDAC
Lintuzumab-225-Actinium	mAb	lintuzumab	CD33ab_monotherapy
MEC	MEC	MEC	MEC
MEC (mitoxantrone 8 mg/m2 )	MEC	MEC	MEC
Supportive	Supportive	Supportive	Supportive
